Dr. Reddy's

Aurigene and Kainomyx to Partner on Anti-Malarial Drug

Aurigene Pharmaceutical Services, the CRDMO arm of India-based Dr. Reddy’s, has signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, a US-based company with a proprietary platform that helps target cytoskeletal proteins of parasites, for the development and commercialization of an affordable anti-malarial drug in in the US, Europe, and in low and middle-income countries.

Akhil Ravi Named CEO of Aurigene Pharmaceutical Services

Dr. Reddy's has appointed Akhil Ravi as CEO for its wholly-owned subsidiary Aurigene Pharmaceutical Services effective Feb. 1, 2022.

Dr. Reddy's Enters into a Licensing Agreement with Gilead for Remdesivir

Erez Israeli Joins Dr. Reddy’s as New Chief Operating Officer

US Law Firm Probes Dr. Reddy’s and PTC

UCB to Sell Established Brands in India to Dr. Reddy’s

Dr. Reddy's Q2 Profit Jumps on New Drugs

Dr. Reddy's CPS Business Expands Manufacturing Operations in Mirfield, UK

Merck KGaA, Dr. Reddy's in Biosimilars Deal

Penicillin: Dr. Reddy's Buys Glaxo's U.S. Business

India's Dr Reddy's Q2 Net Up 32%; Beats Forecast